echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > China Chemical > The European Court of Justice formally annuls the decision to classify the carcinogenicity of titanium dioxide

    The European Court of Justice formally annuls the decision to classify the carcinogenicity of titanium dioxide

    • Last Update: 2023-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the European General Court of Justice annulled the European Commission's decision
    on the classification of titanium dioxide carcinogenicity.

    In February 2020, according to the 14th amendment to the EU CLP Regulation (EC) 1272/2008, the European Commission classified titanium dioxide as inhalation carcinogenicity category 2, i.
    e.
    titanium dioxide powder with an aerodynamic diameter of less than or equal to 10 μm particles is considered potentially carcinogenic by inhalation (H351).

    (For details, please refer to previous articles: titanium dioxide, coatings, cosmetics and other enterprises pay attention!) Titanium dioxide is classified as a suspected carcinogen by the European Union)

    Producers, importers, distributors and downstream users of titanium dioxide have strongly opposed this classification and jointly filed a lawsuit
    with the European General Court.
    Regarding the controversial point on the basis of the classification of titanium dioxide, we also mentioned in an article last year: nearly one-third of employees were physically detected with lung nodules, which are related to formaldehyde removal potions?

    Recently, this controversy, which has lasted for several years, finally ushered in the dawn, the European Court of Justice held that based on the current evidence, the EU Risk Assessment Committee RAC made a clear error in assessing the acceptability and reliability of scientific research on inhalation carcinogenicity, and its assessment conclusion violated the classification and labeling standards of carcinogens established by the EU CLP regulation, because the hazard classification should be based on the intrinsic intrinsic properties of the substance, not the characteristics affected by several factors, if carcinogenicity is only related to certain inhalable titanium dioxide particles and lung load.
    It can only be a specific complementary condition, not an intrinsic property
    of titanium dioxide.

    The decision therefore also requires the European Commission to fill in the correction
    of any legal measure arising from the invalidity of the change in classification within one year.

    The current ruling opinion is undoubtedly a major positive news for the titanium dioxide industry, although the removal of the unified classification will need to wait for further action
    by the European Commission.
    Ruio Technology recommends that enterprises continue to pay attention to the progress of the classification incident and adjust product labels and classifications
    in a timely manner.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.